scholarly journals Microbial evaluation of the effectiveness of different methods for cleansing clear orthodontic retainers: A randomized clinical trial

2016 ◽  
Vol 87 (3) ◽  
pp. 460-465 ◽  
Author(s):  
Rehaf H. Albanna ◽  
Hisham M. Farawanah ◽  
Abdullah M. Aldrees
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Bacterial Species ◽  
In Vitro Tests ◽  
P Value ◽  
Full Time ◽  
Eligibility Criteria ◽  
Double Blind ◽  
Bacterial Quantification

ABSTRACT Objective: To compare effectiveness of brushing an Essix retainer with water only and brushing followed by soaking in one of three commercial cleansing tablets. Materials and Methods: A double-blind, parallel, randomized clinical trial with a split-mouth design was completed with 60 volunteers with specific eligibility criteria assigned to three groups to compare the cleansing effectiveness of brushing an Essix retainer with water only, followed by soaking in one of three alkaline peroxide–based commercial cleansing tablets (Retainer Brite®, Kukis®, and Corega®). Each participant wore an upper Essix retainer (with an electronic microsensor) on a full-time basis for 14 days and used one of the three products on one side of the retainer for 15 min/d. The effectiveness of the cleansing tablets was tested by the scanning electron microscopy, bacterial identification, bacterial quantification, and disk diffusion methods. Results: Bacterial quantification tests demonstrated nonsignificant statistical differences between the control and test sides of the three cleansing tablets: Retainer Brite®, Kukis®, and Corega® (Mann-Whitney test P-values were .6, .37, and .5, respectively). A Kruskal-Wallis test also showed nonstatistical difference in the bacterial counts between the three groups (P-value = .5). In vitro tests showed a minimal inhibition zone of Staphylococcus epidermidis only with Corega® tablets. Conclusions: Using chemical cleansing tablets after mechanical cleansing did not significantly reduce the bacterial count in Essix retainers when compared to use of mechanical cleansing alone. However, the tablets seem to be effective against “cocci” bacterial species.

scholarly journals The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial

Toxins ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 279 ◽  
Author(s):  
Youssef Bennis ◽  
Yan Cluet ◽  
Dimitri Titeca-Beauport ◽  
Najeh El Esper ◽  
Pablo Ureña ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Serum Levels ◽  
Uremic Toxins ◽  
In Vitro Experiments ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Ckd Stage ◽  
Sevelamer Carbonate

High serum levels of gut-derived uremic toxins, especially p-cresyl sulfate (pCS), indoxyl sulfate (IS) and indole acetic acid (IAA), have been linked to adverse outcomes in patients with chronic kidney disease (CKD). Sevelamer carbonate could represent an interesting option to limit the elevation of gut-derived uremic toxins. The aim of the present study was to evaluate the adsorptive effect of sevelamer carbonate on different gut-derived protein-bound uremic toxins or their precursors in vitro, and its impact on the serum levels of pCS, IS and IAA in patients with CKD stage 3b/4. For the in vitro experiments, IAA, p-cresol (precursor of pCS) and indole (precursor of IS), each at a final concentration of 1 or 10 µg/mL, were incubated in centrifugal 30 kDa filter devices with 3 or 15 mg/mL sevelamer carbonate in phosphate-buffered saline at a pH adjusted to 6 or 8. Then, samples were centrifuged and free uremic toxins in the filtrates were analyzed. As a control experiment, the adsorption of phosphate was also evaluated. Additionally, patients with stage 3b/4 CKD (defined as an eGFR between 15 and 45 mL/min per 1.73 m2) were included in a multicenter, double-blind, placebo-controlled, randomized clinical trial. The participants received either placebo or sevelamer carbonate (4.8 g) three times a day for 12 weeks. The concentrations of the toxins and their precursors were measured using a validated high-performance liquid chromatography method with a diode array detector. In vitro, regardless of the pH and concentration tested, sevelamer carbonate did not show adsorption of indole and p-cresol. Conversely, with 10 µg/mL IAA, use of a high concentration of sevelamer carbonate (15 mg/mL) resulted in a significant toxin adsorption both at pH 8 (mean reduction: 26.3 ± 3.4%) and pH 6 (mean reduction: 38.7 ± 1.7%). In patients with CKD stage 3b/4, a 12-week course of treatment with sevelamer carbonate was not associated with significant decreases in serum pCS, IS and IAA levels (median difference to baseline levels: −0.12, 0.26 and −0.06 µg/mL in the sevelamer group vs. 1.97, 0.38 and 0.05 µg/mL in the placebo group, respectively). Finally, in vitro, sevelamer carbonate was capable of chelating a gut-derived uremic toxin IAA but not p-cresol and indole, the precursors of pCS and IS in the gut. In a well-designed clinical study of patients with stage 3b/4 CKD, a 12-week course of treatment with sevelamer carbonate was not associated with significant changes in the serum concentrations of pCS, IS and IAA.

scholarly journals The Effect of Paracetamol on the Patient-Controlled Pain After Coronary Artery Bypass Surgery: A Randomized Clinical Trial Study

2022 ◽  
Author(s):  
Maziar Mahjoubifard ◽  
Yalda Moeini ◽  
Elham Feizabad ◽  
Ali Abdolrazaghnejad
Keyword(s):  
Clinical Trial ◽  
Coronary Artery ◽  
Pain Score ◽  
Randomized Clinical Trial ◽  
Coronary Artery Bypass ◽  
Artery Bypass ◽  
Bypass Graft ◽  
P Value ◽  
Double Blind ◽  
The Mean

Background: Pain is one of the patients' common problems, and usual morbidity after coronary artery bypass graft (CABG). This study aimed to assess the effect of Paracetamol and fentanyl in reducing post-CABG pain. Methods: This double-blind randomized clinical trial was conducted on 160 patients undergoing elective CABG (80 in group F (Fentanyl) and 80 in group P (Paracetamol)), at the cardiac surgery department of hospitals affiliated with Zahedan University of Medical Sciences. In group F, 50μg of Fentanyl (intravenous (IV)) was injected followed by a solution of 10 μg/cc at a rate of 4 cc/hr. For patients in group P, 15 mg/kg of Paracetamol (IV) was administered followed by a solution of 25 μg/cc at a rate of 4 cc/hr. Patients have been infused with the named drugs within the first 24 hours after the operation. Pain severity was assessed by the visual pain score (VAS) tool at baseline, and two, four, eight, twelve, and twenty-four hours after the surgery. Results: The mean of pain score in 12 (P-value=0.002) and 24 (P-value<0.0001) hours after surgery in group P was significantly less than that of group F. The mean heart rate in patients receiving Paracetamol was significantly (P-value = 0.005) less than that of patients receiving Fentanyl for 4 hours after surgery. The mean of increasing creatinine postoperatively in two groups was significant. The mean of increasing AST and ALT postoperatively in group P was significant with no case of liver function impairment. Conclusion: It seems Paracetamol is a good choice for reducing post-CABG pain with no significant complication, although further and more comprehensive research is needed.

Effect of Gamma-oryzanol-enriched Rice Bran Oil on Triglyceride Levels and TG/HDL Ratio in the Patients with Hypertriglyceridemia: Double-Blind Randomized Clinical Trial

2021 ◽  
Vol 104 (Suppl. 1) ◽  
pp. S70-S76
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Rice Bran ◽  
Rice Bran Oil ◽  
Serum Triglyceride ◽  
Treated Group ◽  
Lipid Lowering ◽  
P Value ◽  
Double Blind ◽  
Gamma Oryzanol

Background: Hypertriglyceridemia may contribute to hardening or thickening of the artery walls which increases the risk of stroke and heart disease. Therefore, the normal level of serum triglyceride can prevent both cardiovascular and cerebrovascular diseases. Gamma-oryzanol, a phytosterol compound presents in rice bran oil, has been shown to exhibit lipid-lowering effects in both animals and human. Objective: To evaluate the effect of gamma-oryzanol-enriched-rice bran oil from Thai brown rice, prepared by innovation technology, on plasma triglyceride (TG) level in patients with hypertriglyceridemia. Materials and Methods: Double-blind randomized clinical trial was carried out in 54 subjects with hypertriglyceridemia. They were divided into two groups (27 patients per group) and treated with RBOh (gamma-oryzanol-enriched rice bran oil, 20,000 ppm of gamma-oryzanol), and RBOn (cooking oil, gamma-oryzanol 5,000 ppm). The treatments were performed for 8 weeks. Physical examinations and laboratory tests were performed at weeks 0 (as baseline), 4th and 8th of the study. Lifestyle modifications were conducted in both groups. Results: Significant reduction of plasma TG levels at the 4th and 8th weeks of the treatment were found in RBOh-treated group with p-value = 0.024 and 0.006, respectively. In RBOn-treated group, significant reduction of plasma TG and increase in HDL levels and was observed at the 4th week, but not the 8th week of the treatment, with p-value = 0.001 and 0.020, respectively. TG/HDL cholesterol ratio was significantly reduce at the 4th and 8th week in RBOh-treated group (p-value = 0.011 and 0.048, respectively) and at the 4th week in RBOn-treated group (p-value = 0.003). No serious side effects were found throughout the study period in any group of treatment. Conclusion: Rice bran oil containing gamma oryzanol could reduce the TG level in hypertriglyceridemic patients. The RBOh, gamma oryzanol-enriched rice bran oil, showed prominent effects in reducing serum TG level and TG/HDL ratio. Therefore, RBOh intakes might be able to help prevent the occurrence of cerebrovascular and cardiovascular disease in the patients with hypertriglyceridemia. Keywords: Hypertriglyceridemia, Rice bran oil, Gamma-oryzanol, TG/HDL ratio

Comparing Intradermal Sterile Water with Intravenous Morphine in Reducing Pain in Patients with Renal Colic: A Double-Blind Randomized Clinical Trial

2020 ◽  
Vol 15 (1) ◽  
pp. 76-82
Author(s):  
Javad Mozafari ◽  
Mohammadreza Maleki Verki ◽  
Fatemeh Tirandaz ◽  
Reza Mahjouri
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Renal Colic ◽  
Therapeutic Effects ◽  
Sterile Water ◽  
Morphine Group ◽  
Double Blind ◽  
Water Group ◽  
Intravenous Morphine ◽  
Painful Area

Objective: The present study was conducted to investigate the effect of intradermal administration of sterile water compared to intravenous morphine on patients with renal colic. Methods: This double-blind, randomized clinical trial study was conducted in 2017 to compare the therapeutic effects of intradermal sterile water with those of intravenous morphine on patients with renal colic presenting to the emergency departments (ED) of Imam Khomeini and Golestan Hospitals in Ahvaz, Iran. The first group received 0.5 ml of intradermal sterile water, and the second group 0.1mg/kg of intravenous morphine plus 0.5 ml of intradermal sterile water in the most painful area or the center of the painful area in the flank. The pain severity was measured using a visual analogue scale (VAS), and the medication side-effects were recorded at the beginning of the study and minutes 15, 30,45 and 60. Result: A total of 94 patients were studied in two groups. The mean severity of pain was 2.97 ± 1.51 in the sterile water group and 2.34 ± 1.89 in the morphine group at minute 30 (P=0.042), 2.58 ± 1.43 in the sterile water group and 1 ± 1.23 in the morphine group at minute 45 (p<0.001), and 1.89 ± 1.7 in the sterile water group and 0.52 ± 0.79 in the morphine group at minute 60 (p<0.001). Conclusion: Morphine reduces pain faster and more effectively than intradermal sterile water; nevertheless, treatment with intradermal sterile water can be used as an appropriate surrogate or adjunct therapy for pain control, particularly in special patients or in case of medication scarcity.

Sign in / Sign up

Export Citation Format

Share Document